Safety and efficacy of sodium caprate in promoting oral drug absorption: from in vitro to the clinic

Advanced Drug Delivery Reviews

Volumn 61, Issue 15, 2009, Pages 1427-1449

  Maher, Sam ^a   Leonard, Thomas W ^b   Jacobsen, Jette ^c   Brayden, David J ^a  

^a UNIVERSITY COLLEGE DUBLIN   (Ireland)

^b Citywest Business Park   (Ireland)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Absorption promoter; Clinical trials; Drug delivery platforms; Drug delivery systems; Oral drug delivery; Oral formulation; Sodium caprate (C10)

Indexed keywords

CLINICAL TRIAL; CLINICAL TRIALS; DRUG DELIVERY SYSTEM; ORAL DRUG DELIVERY; ORAL FORMULATION;

ABSORPTION; DRUG DELIVERY; DRUG PRODUCTS; FATTY ACIDS; OLIGONUCLEOTIDES; SODIUM;

DRUG DOSAGE;

3 (3,4 DIHYDROXYPHENYL)LACTIC ACID; ACAMPROSATE; AMPICILLIN; ARDEPARIN; ATENOLOL; BETA LACTAM ANTIBIOTIC; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CAPSITONIN; CAPSULIN; CEFMETAZOLE; CEFOTAXIME; CEFTAZIDIME; CEFTIZOXIME; CLODRONIC ACID; DECANOATE SODIUM; DECANOIC ACID; EBIRATIDE; EPIRUBICIN; HEPARIN; INSULIN; MANNITOL; MEDIUM CHAIN FATTY ACID; OLIGONUCLEOTIDE; PENICILLIN G; PENICILLIN V; PROPRANOLOL; RECOMBINANT EPIDERMAL GROWTH FACTOR; STREPTOKINASE; SULPIRIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASOPRESSIN;

ABDOMINAL PAIN; BURNING SENSATION; CELL MEMBRANE PERMEABILITY; CELL VIABILITY; CYTOTOXICITY; DIARRHEA; DRUG ABSORPTION; DRUG FORMULATION; FOREIGN BODY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INTESTINE ABSORPTION; INTESTINE EPITHELIUM; INTESTINE MUCOSA; LOOSE FECES; NONHUMAN; ORAL DRUG ADMINISTRATION; OTITIS MEDIA; PAIN; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; REVIEW; SINGLE DRUG DOSE;

ADMINISTRATION, ORAL; ANIMALS; DECANOIC ACIDS; DRUG DELIVERY SYSTEMS; DRUG EVALUATION, PRECLINICAL; HUMANS; INTESTINAL ABSORPTION; MODELS, BIOLOGICAL;

EID: 71549130146     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.addr.2009.09.006     Document Type: Review

References (294)

1. Walsh G. Market development of biopharmaceuticals. Genet. Eng. Livestock: New Appl. Interdiscipl. Perspect. 34 (2009) 69-89
2. Goldberg M., and Gomez-Orellana I. Challenges for the oral delivery of macromolecules. Nat. Rev. 2 4 (2003) 289-295
3. Glowka E., Sapin-Minet A., Leroy P., Lulek J., and Maincent P. Preparation and in vitro-in vivo evaluation of salmon calcitonin-loaded polymeric nanoparticles. J. Microencapsul. (2009) 1-12
4. Yasothan U., and Kar S. Osteoporosis: overview and pipeline. Nat. Rev. 7 9 (2008) 725-726
5. Mitri J., and Pittas A.G. Inhaled insulin-what went wrong. Nat. Clin. Pract. Endocrinol. Metab. 5 1 (2009) 24-25
6. Amidon G.L., Lennernas H., Shah V.P., and Crison J.R. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm. Res. 12 3 (1995) 413-420
7. Brandsch M., Knutter I., and Bosse-Doenecke E. Pharmaceutical and pharmacological importance of peptide transporters. J. Pharm. Pharmacol. 60 5 (2008) 543-585
8. Tsukita S., Furuse M., and Itoh M. Multifunctional strands in tight junctions. Nat. Rev. 2 4 (2001) 285-293
9. Shin K., Fogg V.C., and Margolis B. Tight junctions and cell polarity. Annu. Rev. Cell. Dev. Biol. 22 (2006) 207-235
10. Watson C.J., Rowland M., and Warhurst G. Functional modeling of tight junctions in intestinal cell monolayers using polyethylene glycol oligomers. Am. J. Physiol. 281 2 (2001) C388-397
11. Sawada T., Ogawa T., Tomita M., Hayashi M., and Awazu S. Role of paracellular pathway in nonelectrolyte permeation across rat colon epithelium enhanced by sodium caprate and sodium caprylate. Pharm. Res. 8 11 (1991) 1365-1371
12. Ma T.Y., Hollander D., Erickson R.A., Truong H., Nguyen H., and Krugliak P. Mechanism of colonic permeation of inulin: is rat colon more permeable than small intestine?. Gastroenterology 108 1 (1995) 12-20
13. Ambati J., Canakis C.S., Miller J.W., Gragoudas E.S., Edwards A., Weissgold D.J., Kim I., Delori F.C., and Adamis A.P. Diffusion of high molecular weight compounds through sclera. Invest. Ophth. Vis. Sci. 41 5 (2000) 1181-1185
14. Fasano A., and Uzzau S. Modulation of intestinal tight junctions by Zonula occludens toxin permits enteral administration of insulin and other macromolecules in an animal model. J. Clin. Invest. 99 6 (1997) 1158-1164
15. Lipinski C.A., Lombardo F., Dominy B.W., and Feeney P.J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 46 1-3 (2001) 3-26
16. Madara J.L., and Dharmsathaphorn K. Occluding junction structure-function relationships in a cultured epithelial monolayer. J. Cell Biol. 101 6 (1985) 2124-2133
17. Windsor E., and Cronheim G.E. Gastro-intestinal absorption of heparin and synthetic heparinoids. Nature 190 477 (1961) 263-264
18. Johnson P.H., Frank D., and Costantino H.R. Discovery of tight junction modulators: significance for drug development and delivery. Drug Discov. Today 13 5-6 (2008) 261-267
19. Kondoh M., Yoshida T., Kakutani H., and Yagi K. Targeting tight junction proteins-significance for drug development. Drug Discov. Today 13 3-4 (2008) 180-186
20. Gonzalez-Mariscal L., Hernandez S., and Vega J. Inventions designed to enhance drug delivery across epithelial and endothelial cells through the paracellular pathway. Recent Pat. Drug Deliv. Formul. 2 2 (2008) 145-176
21. Koga K., Kusawake Y., Ito Y., Sugioka N., Shibata N., and Takada K. Enhancing mechanism of Labrasol on intestinal membrane permeability of the hydrophilic drug gentamicin sulfate. Eur. J. Pharm. Biopharm. 64 1 (2006) 82-91
22. Lindmark T., Soderholm J.D., Olaison G., Alvan G., Ocklind G., and Artursson P. Mechanism of absorption enhancement in humans after rectal administration of ampicillin in suppositories containing sodium caprate. Pharm. Res. 14 7 (1997) 930-935
23. Murakami T., Kawakita M., Kishimoto M., Higashi Y., Amagase H., Hayashi T., Nojima N., Fuwa T., and Yata N. Intravenous and subcutaneous pharmacokinetics and rectal bioavailability of human epidermal growth factor in the presence of absorption promoter in rats. Int. J. Pharm. 46 1-2 (1988) 9-17
24. Leonard T.W., Lynch J., McKenna M.J., and Brayden D.J. Promoting absorption of drugs in humans using medium-chain fatty acid-based solid dosage forms: GIPET. Expert Opin. Drug Deliv. 3 5 (2006) 685-692
25. Coughlan D.C., O'Toole E., and Leonard T.W. Advancing gastrointestinal permeation enhancement formulations into the clinical: GIPET™. In: Rathbone M.J. (Ed). Modified-release Drug Delivery Technology (Drugs and the Pharmaceutical Science). 2nd edition Vol. 183 (2008), Informa Healthcare, New York 239-249
26. Tillman L.G., Geary R.S., and Hardee G.E. Oral delivery of antisense oligonucleotides in man. J. Pharm. Sci. 97 1 (2008) 225-236
27. Kovarik J.M., Mueller E.A., van Bree J.B., Fluckiger S.S., Lange H., Schmidt B., Boesken W.H., Lison A.E., and Kutz K. Cyclosporine pharmacokinetics and variability from a microemulsion formulation-a multicenter investigation in kidney transplant patients. Transplantation 58 6 (1994) 658-663
28. Fjellestad-Paulsen A., Hoglund P., Lundin S., and Paulsen O. Pharmacokinetics of 1-deamino-8-d-arginine vasopressin after various routes of administration in healthy volunteers. Clin. Endocrinol. 38 2 (1993) 177-182
29. Gomez-Orellana I. Strategies to improve oral drug bioavailability. Expert Opin. Drug Deliv. 2 3 (2005) 419-433
30. Rautio J., Kumpulainen H., Heimbach T., Oliyai R., Oh D., Jarvinen T., and Savolainen J. Prodrugs: design and clinical applications. Nat. Rev. 7 3 (2008) 255-270
31. Brown L.R. Commercial challenges of protein drug delivery. Expert Opin. Drug Deliv. 2 1 (2005) 29-42
32. Gomez-Orellana I., and Paton D.R. Advances in the oral delivery of proteins. Exp. Opin. Ther. Patents 9 3 (1999) 247-253
33. Asada H., Douen T., Waki M., Adachi S., Fujita T., Yamamoto A., and Muranishi S. Absorption characteristics of chemically modified-insulin derivatives with various fatty acids in the small and large intestine. J. Pharm. Sci. 84 6 (1995) 682-687
34. Fujita T., Fujita T., Morikawa K., Tanaka H., Iemura O., Yamamoto A., and Muranishi S. Improvement of intestinal absorption of human calcitonin by chemical modification with fatty acids: synergistic effects of acylation and absorption enhancers. Int. J. Pharm. 134 1-2 (1996) 47-57
35. Uchiyama T., Kotani A., Tatsumi H., Kishida T., Okamoto A., Okada N., Murakami M., Fujita T., Fujiwara Y., Kiso Y., Muranishi S., and Yamamoto A. Development of novel lipophilic derivatives of DADLE (leucine enkephalin analogue): intestinal permeability characateristics of DADLE derivatives in rats. Pharm. Res. 17 12 (2000) 1461-1467
36. Yodoya E., Uemura K., Tenma T., Fujita T., Murakami M., Yamamoto A., and Muranishi S. Enhanced permeability of tetragastrin across the rat intestinal membrane and its reduced degradation by acylation with various fatty acids. J. Pharmacol. Exp. Ther. 271 3 (1994) 1509-1513
37. Fujita T., Morishita Y., Ito H., Kuribayashi D., Yamamoto A., and Muranishi S. Enhancement of the small intestinal uptake of phenylalanylglycine via a H+/oligopeptide transport system by chemical modification with fatty acids. Life Sci. 61 25 (1997) 2455-2465
38. Yamamoto A., Morishita Y., Sugishita S., Hayami T., Okada N., Fujita T., and Muranishi S. Enhanced permeability of phenylalanyl-glycine (Phe-Gly) across the intestinal membranes by chemical modification with various fatty acids. Drug Metab. Pharmacokinet. 18 1 (2003) 23-32
39. Youn Y.S., Jung J.Y., Oh S.H., Yoo S.D., and Lee K.C. Improved intestinal delivery of salmon calcitonin by Lys18-amine specific PEGylation: stability, permeability, pharmacokinetic behavior and in vivo hypocalcemic efficacy. J. Control. Release 114 3 (2006) 334-342
40. Cetin M., Youn Y.S., Capan Y., and Lee K.C. Preparation and characterization of salmon calcitonin-biotin conjugates. AAPS PharmSciTech. 9 4 (2008) 1191-1197
41. Shah R.B., Ahsan F., and Khan M.A. Oral delivery of proteins: progress and prognostication. Crit. Rev. Ther. Drug Carrier Syst. 19 2 (2002) 135-169
42. Clement S., Dandona P., Still J.G., and Kosutic G. Oral modified insulin (HIM2) in patients with type 1 diabetes mellitus: results from a phase I/II clinical trial. Metabolism 53 1 (2004) 54-58
43. Chin C.M., Gutierrez M., Still J.G., and Kosutic G. Pharmacokinetics of modified oral calcitonin product in healthy volunteers. Pharmacotherapy 24 8 (2004) 994-1001
44. Petrus A.K., Vortherms A.R., Fairchild T.J., and Doyle R.P. Vitamin B12 as a carrier for the oral delivery of insulin. Chem. Med. Chem. 2 12 (2007) 1717-1721
45. Smart J.D. The basics and underlying mechanisms of mucoadhesion. Adv. Drug Deliv. Rev. 57 11 (2005) 1556-1568
46. Peppas N.A., Thomas J.B., and McGinty J. Molecular aspects of mucoadhesive carrier development for drug delivery and improved absorption. J. Biomater. Sci. 20 1 (2009) 1-20
47. Bernkop-Schnurch A. Thiomers: a new generation of mucoadhesive polymers. Adv. Drug Deliv. Rev. 57 11 (2005) 1569-1582
48. Wong T.W. Chitosan and its use in design of insulin delivery system. Recent Pat. Drug Deliv. Formul. 3 1 (2009) 8-25
49. Varum F.J., McConnell E.L., Sousa J.J., Veiga F., and Basit A.W. Mucoadhesion and the gastrointestinal tract. Crit. Rev. Ther. Drug Carrier Syst. 25 3 (2008) 207-258
50. Rossi S., Sandri G., and Caramella C.M. Buccal drug delivery: a challenge already won?. Drug Discov. Today 2 1 (2005) 59-65
51. Galindo-Rodriguez S.A., Allemann E., Fessi H., and Doelker E. Polymeric nanoparticles for oral delivery of drugs and vaccines: a critical evaluation of in vivo studies. Crit. Rev. Ther. Drug Carrier Syst. 22 5 (2005) 419-464
52. Reis C.P., Veiga F.J., Ribeiro A.J., Neufeld R.J., and Damge C. Nanoparticulate biopolymers deliver insulin orally eliciting pharmacological response. J. Pharm. Sci. 97 12 (2008) 5290-5305
53. Forrest M.L., and Kwon G.S. Clinical developments in drug delivery nanotechnology. Adv. Drug Deliv. Rev. 60 8 (2008) 861-862
54. Brayden D.J., and Baird A.W. Apical membrane receptors on intestinal M cells: potential targets for vaccine delivery. Adv. Drug Deliv. Rev. 56 6 (2004) 721-726
55. Brayden D.J., Jepson M.A., and Baird A.W. Keynote review: intestinal Peyer's patch M cells and oral vaccine targeting. Drug Discov. Today 10 17 (2005) 1145-1157
56. Lai S.K., Wang Y.Y., and Hanes J. Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues. Adv. Drug Deliv. Rev. 61 2 (2009) 158-171
57. Petrus A.K., Fairchild T.J., and Doyle R.P. Traveling the vitamin B12 pathway: oral delivery of protein and peptide drugs. Angew. Chem. Int. Edit. 48 6 (2009) 1022-1028
58. Fahr A., and Liu X. Drug delivery strategies for poorly water-soluble drugs. Expert Opin. Drug Deliv. 4 4 (2007) 403-416
59. Merisko-Liversidge E., McGurk S.L., and Liversidge G.G. Insulin nanoparticles: a novel formulation approach for poorly water soluble Zn-insulin. Pharm. Res. 21 9 (2004) 1545-1553
60. Jensen-Jarolim E., Gajdzik L., Haberl I., Kraft D., Scheiner O., and Graf J. Hot spices influence permeability of human intestinal epithelial monolayers. J. Nutr. 128 3 (1998) 577-581
61. Ilback N.G., Nyblom M., Carlfors J., Fagerlund-Aspenstrom B., Tavelin S., and Glynn A.W. Do surface-active lipids in food increase the intestinal permeability to toxic substances and allergenic agents?. Med. Hypotheses 63 4 (2004) 724-730
62. Ma T.Y., Nguyen D., Bui V., Nguyen H., and Hoa N. Ethanol modulation of intestinal epithelial tight junction barrier. Am. J. Physiol. 276 4 Pt 1 (1999) G965-974
63. Playford R.J., MacDonald C.E., Calnan D.P., Floyd D.N., Podas T., Johnson W., Wicks A.C., Bashir O., and Marchbank T. Co-administration of the health food supplement, bovine colostrum, reduces the acute non-steroidal anti-inflammatory drug-induced increase in intestinal permeability. Clin. Sci. (Lond.) 100 6 (2001) 627-633
64. Fasano A., Baudry B., Pumplin D.W., Wasserman S.S., Tall B.D., Ketley J.M., and Kaper J.B. Vibrio cholerae produces a second enterotoxin, which affects intestinal tight junctions. Proc. Natl. Acad. Sci. U.S.A. 88 12 (1991) 5242-5246
65. Hollander D. Intestinal permeability, leaky gut, and intestinal disorders. Curr. Gastroenterol. Rep. 1 5 (1999) 410-416
66. Gisolfi C.V. Is the GI system built for exercise?. News Physiol. Sci. 15 (2000) 114-119
67. Chien J.Y., and Ho R.J. Drug delivery trends in clinical trials and translational medicine. J. Pharm. Sci. 97 7 (2008) 2543-2547
68. Madara J.L., Moore R., and Carlson S. Alteration of intestinal tight junction structure and permeability by cytoskeletal contraction. Am. J. Physiol. 253 6 Pt 1 (1987) C854-861
69. Ma T.Y., Tran D., Hoa N., Nguyen D., Merryfield M., and Tarnawski A. Mechanism of extracellular calcium regulation of intestinal epithelial tight junction permeability: role of cytoskeletal involvement. Microsc. Res. Tech. 51 2 (2000) 156-168
70. Hochman J., and Artursson P. Mechanisms of absorption enhancement and tight junction regulation. J. Control. Release 29 3 (1994) 253-267
71. Fernandez Miyakawa M.E., Pistone Creydt V., Uzal F.A., McClane B.A., and Ibarra C. Clostridium perfringens enterotoxin damages the human intestine in vitro. Infect. Immun. 73 12 (2005) 8407-8410
72. Salama N.N., Eddington N.D., and Fasano A. Tight junction modulation and its relationship to drug delivery. Adv. Drug Deliv. Rev. 58 1 (2006) 15-28
73. Kondoh M., Masuyama A., Takahashi A., Asano N., Mizuguchi H., Koizumi N., Fujii M., Hayakawa T., Horiguchi Y., and Watanbe Y. A novel strategy for the enhancement of drug absorption using a claudin modulator. Mol. Pharmacol. 67 3 (2005) 749-756
74. Kondoh M., Takahashi A., Fujii M., Yagi K., and Watanabe Y. A novel strategy for a drug delivery system using a claudin modulator. Biol. Pharm. Bull. 29 9 (2006) 1783-1789
75. Malkov D., Angelo R., Wang H.Z., Flanders E., Tang H., and Gomez-Orellana I. Oral delivery of insulin with the eligen technology: mechanistic studies. Curr. Drug Deliv. 2 2 (2005) 191-197
76. Kidron M., Dinh S., Menachem Y., Abbas R., Variano B., Goldberg M., Arbit E., and Bar-On H. A novel per-oral insulin formulation: proof of concept study in non-diabetic subjects. Diabet. Med. 21 4 (2004) 354-357
77. Hoffman A., and Qadri B. Eligen insulin-a system for the oral delivery of insulin for diabetes. IDrugs 11 6 (2008) 433-441
78. Arbit E., Goldberg M., Gomez-Orellana I., and Majuru S. Oral heparin: status review. Thromb. J. 4 (2006) 6
79. Buclin T., Cosma Rochat M., Burckhardt P., Azria M., and Attinger M. Bioavailability and biological efficacy of a new oral formulation of salmon calcitonin in healthy volunteers. J. Bone Miner. Res. 17 8 (2002) 1478-1485
80. Welt F.G., Woods T.C., and Edelman E.R. Oral heparin prevents neointimal hyperplasia after arterial injury: inhibitory potential depends on type of vascular injury. Circulation 104 25 (2001) 3121-3124
81. Riley M.G., Castelli M.C., and Paehler E.A. Subchronic oral toxicity of salcaprozate sodium (SNAC) in Sprague-Dawley and Wistar rats. Int J Toxicol 28 4 (2009) 278-293
82. New R. US Patent 730376 (2004)
83. Chen F.-J., Patel M.V., and Fikstad D.T. US Patent 6458383 (2002)
84. Werle M., Takeuchi H., and Bernkop-Schnurch A. Modified chitosans for oral drug delivery. J. Pharm. Sci. 98 5 (2009) 1643-1656
85. Mourya V.K., and Inamdar N.N. Trimethyl chitosan and its applications in drug delivery. J. Mater. Sci. 20 5 (2009) 1057-1079
86. Thanou M., Verhoef J.C., and Junginger H.E. Oral drug absorption enhancement by chitosan and its derivatives. Adv. Drug Deliv. Rev. 52 2 (2001) 117-126
87. Bernstein G. Delivery of insulin to the buccal mucosa utilizing the RapidMist system. Expert Opin. Drug Deliv. 5 9 (2008) 1047-1055
88. Lower E.S. Capric acid-uses and properties, part 1. Manufact. Chem. 55 5 (1984) 61-63
89. Padley F.B., Gunstone F.D., and Harwood J.L. Occurrence and characteristics of oils and fats. In: Gunstone F.D., Harwood J.L., and Padley F.B. (Eds). The Lipid Handbook (1994), Chapman and Hall 47-224
90. Jensen R.G. Fatty acids in milk and dairy products. In: Chow C.K. (Ed). Fatty Acids in Foods and Their Implications (2000), Marcel Dekker, NY 109-123
91. Oro L., and Wretlind A. Pharmacological effects of fatty acids, triolein and cottonseed oil. Acta Pharmacol. Toxicol. 18 (1961) 141-152
92. Smyth Jr. H.F., Carpenter C.P., Weil C.S., Pozzani U.C., and Striegel J.A. Range-finding toxicity data: list VI. Am. Ind. Hyg. Assoc. J23 (1962) 95-107
93. Mori K. Production of gastric lesions in the rat by the diet containing fatty acids. Gan. 44 4 (1953) 421-427
94. Anonymous, Salts of fatty acids, In: Food additives permitted for direct addition to food for human consumption, US Food and Drug Administration, (2008) CFR 21, Part 3, section 172.860.
95. Anonymous, Evaluation of certain food additives and contaminants. 29th report of the joint FAO/WHO Expert Committee on Food Additives. WHO technical report series (1986) No. 733.
96. Kitao K., and Nishimura K. US Patent 4338306 (1982)
97. Kakeya K., Kitao K., and Nishimura K. Japan Patent 80315 (1982)
98. Kitao K.K., and Nishimura K. Japan. Patent 149209 (1980)
99. Yata N., Higashi Y., Murakami T., Yamajo R., Wu W.M., Taku K., Sasaki Y., and Hideshima Y. A possible mechanism of absorption promoters. J. Pharmacobiodyn. 6 4 (1983) S78-S78
100. Shima M., Yohdoh K., Yamaguchi M., Kimura Y., Adachi S., and Matsuno R. Effects of medium-chain fatty acids and their acylglycerols on the transport of penicillin V across Caco-2 cell monolayers. Biosci. Biotechnol. and Biochem. 61 7 (1997) 1150-1155
101. Cho S.Y., Kim J.S., Li H., Shim C., Linhardt R.J., and Kim Y.S. Enhancement of paracellular transport of heparin disaccharide across Caco-2 cell monolayers. Arch. Pharm. Res. 25 1 (2002) 86-92
102. Kim I.W., Yoo H.J., Song I.S., Chung Y.B., Moon D.C., Chung S.J., and Shim C.K. Effect of excipients on the stability and transport of recombinant human epidermal growth factor (rhEGF) across Caco-2 cell monolayers. Arch. Pharm. Res. 26 4 (2003) 330-337
103. Anderberg E.K., Lindmark T., and Artursson P. Sodium caprate elicits dilatations in human intestinal tight junctions and enhances drug absorption by the paracellular route. Pharm. Res. 10 6 (1993) 857-864
104. Lindmark T., Kimura Y., and Artursson P. Absorption enhancement through intracellular regulation of tight junction permeability by medium chain fatty acids in Caco-2 cells. J. Pharmacol. Exp. Ther. 284 1 (1998) 362-369
105. Shima M., Kimura Y., Adachi S., and Matsuno R. Recovery of Caco-2 cell monolayers to normal from the transport-enhanced state induced by capric acid sodium salt and its monoacylglycerol. Biosci. Biotechnol. and Biochem. 63 4 (1999) 680-687
106. Chao A.C., Nguyen J.V., Broughall M., Griffin A., Fix J.A., and Daddona P.E. In vitro and in vivo evaluation of effects of sodium caprate on enteral peptide absorption and on mucosal morphology. Int. J. Pharm. 191 1 (1999) 15-24
107. Sakai M., Imai T., Ohtake H., and Otagiri M. Cytotoxicity of absorption enhancers in Caco-2 cell monolayers. J. Pharm. Pharmacol. 50 10 (1998) 1101-1108
108. Quan Y.S., Hattori K., Lundborg E., Fujita T., Murakami M., Muranishi S., and Yamamoto A. Effectiveness and toxicity screening of various absorption enhancers using Caco-2 cell monolayers. Biol. Pharm. Bull. 21 6 (1998) 615-620
109. Sugiyama T., Yamamoto A., Kawabe Y., Uchiyama T., Quan Y.S., and Muranishi S. Effects of various absorption enhancers on the intestinal absorption of water soluble drugs by in vitro Ussing chamber method: correlation with an in situ absorption experiment. Biol. Pharm. Bull. 20 7 (1997) 812-814
110. Soderholm J.D., Oman H., Blomquist L., Veen J., Lindmark T., and Olaison G. Reversible increase in tight junction permeability to macromolecules in rat ileal mucosa in vitro by sodium caprate, a constituent of milk fat. Dig. Dis. Sci. 43 7 (1998) 1547-1552
111. S. Maher, R. Kennelly, V.A. Bzik, A. Baird, X. Wang, D.C. Winters, D.J. Brayden, Evaluation of intestinal absorption enhancement and local mucosal toxicity of two promoters. I. Studies in Isolated rat and human colonic mucosae. Eur. J. Pharm. Sci. (2009) (In Press, doi:10.1016/j.ejps.2009.09.001).
112. Wallon C., Braaf Y., Wolving M., Olaison G., and Soderholm J.D. Endoscopic biopsies in Ussing chambers evaluated for studies of macromolecular permeability in the human colon. Scand. J. Gastroenterol. 40 5 (2005) 586-595
113. S. Maher, X. Wang, V.A. Bzik, S. McClean, D.J. Brayden, Evaluation of intestinal absorption and mucosal toxicity using two promoters. II. Rat instillation and perfusion studies. Eur. J. Pharm. Sci. (In Press, doi:10.1016/j.ejps.2009.07.011).
114. Lindmark T., Schipper N., Lazorova L., de Boer A.G., and Artursson P. Absorption enhancement in intestinal epithelial Caco-2 monolayers by sodium caprate: assessment of molecular weight dependence and demonstration of transport routes. J. Drug. Target. 5 3 (1998) 215-223
115. Tomita M., Hayashi M., Horie T., Ishizawa T., and Awazu S. Enhancement of colonic drug absorption by the transcellular permeation route. Pharm. Res. 5 12 (1988) 786-789
116. Ishizawa T., Hayashi M., and Awazu S. Enhancement of jejunal and colonic absorption of fosfomycin by promoters in the rat. J. Pharm. Pharmacol. 39 11 (1987) 892-895
117. Muranushi N., Mack E., and Kim S.W. The effects of fatty-acids and their derivatives on the intestinal-absorption of insulin in rat. Drug Dev. Ind. Pharm. 19 8 (1993) 929-941
118. Mizuno A., Ueda M., and Kawanishi G. Effects of salicylate and other enhancers on rectal absorption of erythropoietin in rats. J. Pharm. Pharmacol. 44 7 (1992) 570-573
119. Watanabe Y., Mizufune Y., Kubomura A., Kiriyama M., Utoguchi N., and Matsumoto M. Studies of drug delivery systems for a therapeutic agent used in osteoporosis. I. Pharmacodynamics (hypocalcemic effect) of elcatonin in rabbits following rectal administration of hollow-type suppositories containing elcatonin. Biol. Pharm. Bull. 21 11 (1998) 1187-1190
120. Baluom M., Friedman M., and Rubinstein A. The importance of intestinal residence time of absorption enhancer on drug absorption and implication on formulative considerations. Int. J. Pharm. 176 1 (1998) 21-30
121. Fix J.A. Strategies for delivery of peptides utilizing absorption-enhancing agents. J. Pharm. Sci. 85 12 (1996) 1282-1285
122. Raoof A.A., Ramtoola Z., McKenna B., Yu R.Z., Hardee G., and Geary R.S. Effect of sodium caprate on the intestinal absorption of two modified antisense oligonucleotides in pigs. Eur. J. Pharm. Sci. 17 3 (2002) 131-138
123. Takahashi K., Murakami T., Yumoto R., Hattori T., Higashi Y., and Yata N. Decanoic acid induced enhancement of rectal absorption of hydrophilic compounds in rats. Pharm. Res. 11 10 (1994) 1401-1404
124. Jorgensen J., Holtug K., Jeppesen P.B., and Mortensen P.B. Human rectal absorption of short- and medium-chain C2-C10 fatty acids. Scand. J. Gastroenterol. 33 6 (1998) 590-594
125. Narkar Y., Burnette R., Bleher R., Albrecht R., Kandela A., and Robinson J.R. Evaluation of mucosal damage and recovery in the gastrointestinal tract of rats by a penetration enhancer. Pharm. Res. 25 1 (2008) 25-38
126. Baluom M., Friedman M., Assaf P., Haj-Yehia A.I., and Rubinstein A. Synchronized release of sulpiride and sodium decanoate from HPMC matrices: a rational approach to enhance sulpiride absorption in the rat intestine. Pharm. Res. 17 9 (2000) 1071-1076
127. Schiller C., Frohlich C.P., Giessmann T., Siegmund W., Monnikes H., Hosten N., and Weitschies W. Intestinal fluid volumes and transit of dosage forms as assessed by magnetic resonance imaging. Aliment. Pharmacol. Ther. 22 10 (2005) 971-979
128. De Boer A.G., and Breimer D. GI-tract absorption enhancement: general introduction and simulation of time- concentration-effect profiles of absorption enhancers. In: De Boer A.G. (Ed). Drug Absorption Enhancement Concepts, Possibilities, Limitations and Trends (1994), Harwood Academic Publishers 155-175
129. van Hoogdalem E., de Boer A.G., and Breimer D.D. Pharmacokinetics of rectal drug administration, Part I. General considerations and clinical applications of centrally acting drugs. Clin. Pharmacokinet. 21 1 (1991) 11-26
130. Hardee G., Geary R., Tillman L.G., Bradley J., Su J., Dokka S., and Wedel M. A phase I study of orally administered ISIS 301012 for the reduction of ApoB-100 and LDL-cholesterol. AAPS PharmSciTech 8 S1 (2006)
131. Hardee G.E., Tillman L.G., and Geary R.S. Routes and formulation for the delivery of antisense oligonucleotides. In: Crooke S.T. (Ed). Antisense Drug Technology Principle, Strategies and Applications (2008), CRC press 217-236
132. Burcham D.L., Aungst B.A., Hussain M., Gorko M.A., Quon C.Y., and Huang S.M. The effect of absorption enhancers on the oral absorption of the GP IIB/IIIA receptor antagonist, DMP 728, in rats and dogs. Pharm. Res. 12 12 (1995) 2065-2070
133. Weinbach S., Tillman L.G., Geary R.S., and Hardee G.E. US patent application 2005/0196443 (2005)
134. Takatsuka S., Kitazawa T., Morita T., Horikiri Y., and Yoshino H. Enhancement of intestinal absorption of poorly absorbed hydrophilic compounds by simultaneous use of mucolytic agent and non-ionic surfactant. Eur. J. Pharm. Biopharm. 62 1 (2006) 52-58
135. Umejima H., Kikuchi A., Kim N.S., Uchida T., and Goto S. Preparation and evaluation of Eudragit gels. VIII. Rectal absorption of 5-fluorouracil from Eudispert hv gels in rats. J. Pharm. Sci. 84 2 (1995) 199-202
136. Atuma C., Strugala V., Allen A., and Holm L. The adherent gastrointestinal mucus gel layer: thickness and physical state in vivo. Am. J. Physiol. Gastrointest. Liver Physiol. 280 5 (2001) G922-929
137. Woodley J.F. Enzymatic barriers for GI peptide and protein delivery. Crit. Rev. Ther. Drug Carrier Syst. 11 2-3 (1994) 61-95
138. Haupt S., and Rubinstein A. The colon as a possible target for orally administered peptide and protein drugs. Crit. Rev. Ther. Drug Carrier Syst. 19 6 (2002) 499-551
139. Van den Mooter G. Colon drug delivery. Expert opin. Drug Deliv. 3 1 (2006) 111-125
140. Lee V.H., Yamamoto A., and Kompella U.B. Mucosal penetration enhancers for facilitation of peptide and protein drug absorption. Crit. Rev. Ther. Drug Carrier Syst. 8 2 (1991) 91-192
141. Muranishi S. Absorption barriers and absorption promoters in the intestine. In: Breimer D.D., and Speiser P. (Eds). Topics in Pharmaceutical Science (1987), Elsevier B.V., Amsterdam 445-455
142. Yamamoto A., Okagawa T., Kotani A., Uchiyama T., Shimura T., Tabata S., Kondo S., and Muranishi S. Effects of different absorption enhancers on the permeation of ebiratide, an ACTH analogue, across intestinal membranes. J. Pharm. Pharmacol. 49 11 (1997) 1057-1061
143. Uchiyama T., Sugiyama T., Quan Y.S., Kotani A., Okada N., Fujita T., Muranishi S., and Yamamoto A. Enhanced permeability of insulin across the rat intestinal membrane by various absorption enhancers: their intestinal mucosal toxicity and absorption-enhancing mechanism of n-lauryl-beta-d-maltopyranoside. J. Pharm. Pharmacol. 51 11 (1999) 1241-1250
144. Tomita M., Sawada T., Ogawa T., Ouchi H., Hayashi M., and Awazu S. Differences in the enhancing effects of sodium caprate on colonic and jejunal drug absorption. Pharm. Res. 9 5 (1992) 648-653
145. 2EDTA and sodium glycocholate on intestinal-absorption of insulin. Biol. Pharm. Bull. 16 1 (1993) 68-72
146. Fetih G., Lindberg S., Itoh K., Okada N., Fujita T., Habib F., Artersson P., Attia M., and Yamamoto A. Improvement of absorption enhancing effects of n-dodecyl-beta-d-maltopyranoside by its colon-specific delivery using chitosan capsules. Int. J. Pharm. 293 1-2 (2005) 127-135
147. Muranishi S., and Yamamoto A. Mechanisms of absorption enhancement through gastrointestinal epithelium. In: De Boer A.G. (Ed). Drug Absorption Enhancement Concepts, Possibilities, Limitations and Trends (1994), Harwood Academic 67-100
148. Mackay M., Phillips J., and Hastewell J. Peptide drug delivery: colonic and rectal absorption. Adv. Drug Deliv. Rev. 28 2 (1997) 253-273
149. Gao Y., He L., Katsumi H., Sakane T., Fujita T., and Yamamoto A. Improvement of intestinal absorption of water-soluble macromolecules by various polyamines: intestinal mucosal toxicity and absorption-enhancing mechanism of spermine. Int. J. Pharm. 354 1-2 (2008) 126-134
150. Fetih G., Habib F., Okada N., Fujita T., Attia M., and Yamamoto A. Nitric oxide donors can enhance the intestinal transport and absorption of insulin and [Asu(1, 7)]-eel calcitonin in rats. J. Control. Release 106 3 (2005) 287-297
151. Fetih G., Habib F., Katsumi H., Okada N., Fujita T., Attia M., and Yamamoto A. Excellent absorption enhancing characteristics of NO donors for improving the intestinal absorption of poorly absorbable compound compared with conventional absorption enhancers. Drug Metab. Pharmacokinet. 21 3 (2006) 222-229
152. Lindmark T., Nikkila T., and Artursson P. Mechanisms of absorption enhancement by medium chain fatty acids in intestinal epithelial Caco-2 cell monolayers. J. Pharmacol. Exp. Ther. 275 2 (1995) 958-964
153. Suzuki T., and Hara H. Difructose anhydride III and sodium caprate activate paracellular transport via different intracellular events in Caco-2 cells. Life Sci. 79 4 (2006) 401-410
154. Sakai M., Imai T., Ohtake H., Azuma H., and Otagiri M. Effects of absorption enhancers on cytoskeletal actin filaments in Caco-2 cell monolayers. Life Sci. 63 1 (1998) 45-54
155. Kimura Y., Hosoda Y., Yamaguchi M., Nagano H., Shima M., Adachi S., and Matsuno R. Effects of medium-chain fatty acids on intracellular calcium levels and the cytoskeleton in human intestinal (Caco-2) cell monolayers. Biosci. Biotechnol. Biochem. 65 4 (2001) 743-751
156. Soderholm J.D., Olaison G., Peterson K.H., Franzen L.E., Lindmark T., Wiren M., Tagesson C., and Sjodahl R. Augmented increase in tight junction permeability by luminal stimuli in the non-inflamed ileum of Crohn's disease. Gut 50 3 (2002) 307-313
157. Coyne C.B., Ribeiro C.M., Boucher R.C., and Johnson L.G. Acute mechanism of medium chain fatty acid-induced enhancement of airway epithelial permeability. J. Pharmacol. Exp. Ther. 305 2 (2003) 440-450
158. Coyne C.B., Kelly M.M., Boucher R.C., and Johnson L.G. Enhanced epithelial gene transfer by modulation of tight junctions with sodium caprate. Am. J. Respir. Cell Mol. Biol. 23 5 (2000) 602-609
159. Sugibayashi K., Onuki Y., and Takayama K. Displacement of tight junction proteins from detergent-resistant membrane domains by treatment with sodium caprate. Eur. J. Pharm. Sci. 36 2-3 (2009) 246-253
160. Kurasawa M., Kuroda S., Kida N., Murata M., Oba A., Yamamoto T., and Sasaki H. Regulation of tight junction permeability by sodium caprate in human keratinocytes and reconstructed epidermis. Biochem. Biophys. Res. Commun. 381 2 (2009) 171-175
161. Tomita M., Hayashi M., and Awazu S. Absorption-enhancing mechanism of sodium caprate and decanoylcarnitine in Caco-2 cells. J. Pharmacol. Exp. Ther. 272 2 (1995) 739-743
162. Helenius A., and Simons K. Solubilization of membranes by detergents. Biochim. Biophys. Acta 415 1 (1975) 29-79
163. Turner J.R. 'Putting the squeeze' on the tight junction: understanding cytoskeletal regulation. Semin. Cell Dev. Biol. 11 4 (2000) 301-308
164. Imai T., Sakai M., Ohtake H., Azuma H., and Otagiri M. Absorption-enhancing effect of glycyrrhizin induced in the presence of capric acid. Int. J. Pharm. 294 1-2 (2005) 11-21
165. Tomita M., Hayashi M., and Awazu S. Absorption-enhancing mechanism of EDTA, caprate, and decanoylcarnitine in Caco-2 cells. J. Pharm. Sci. 85 6 (1996) 608-611
166. Hayashi M., Sakai T., Hasegawa Y., Nishikawahara T., Tomioka H., Iida A., Shimizu N., Tomita M., and Awazu S. Physiological mechanism for enhancement of paracellular drug transport. J. Control. Release 62 1-2 (1999) 141-148
167. Shimazaki T., Tomita M., Sadahiro S., Hayashi M., and Awazu S. Absorption-enhancing effects of sodium caprate and palmitoyl carnitine in rat and human colons. Dig. Dis. Sci. 43 3 (1998) 641-645
168. Feighery L.M., Cochrane S.W., Quinn T., Baird A.W., O'Toole D., Owens S.E., O'Donoghue D., Mrsny R.J., and Brayden D.J. Myosin light chain kinase inhibition: correction of increased intestinal epithelial permeability in vitro. Pharm. Res. 25 6 (2008) 1377-1386
169. Takahashi H., Shibasaki T., Takeshita K., Kaiho F., and Hayashi M. The enhancing mechanism of capric acid (C10) from a suppository on rectal drug absorption through a paracellular pathway. Biol. Pharm. Bull. 20 4 (1997) 446-448
170. Kimura Y., Hosoda Y., Shima M., Adachi S., and Matsuno R. Physico-chemical properties of fatty acids for assessing the threshold concentration to enhance the absorption of a hydrophilic substance. Biosci. Biotechnol. Biochem. 62 3 (1998) 443-447
171. Lo Y.L., and Huang J.D. Effects of sodium deoxycholate and sodium caprate on the transport of epirubicin in human intestinal epithelial Caco-2 cell layers and everted gut sacs of rats. Biochem. Pharmacol. 59 6 (2000) 665-672
172. Small D.M. Surface and bulk interactions of lipids and water with a classification of biologically active lipids based on these interactions. Fed. Proc. 29 4 (1970) 1320-1326
173. Lichtenberg D., Robson R.J., and Dennis E.A. Solubilization of phospholipids by detergents. Structural and kinetic aspects. Biochim Biophys Acta 737 2 (1983) 285-304
174. Namani T., and Walde P. From decanoate micelles to decanoic acid/dodecylbenzenesulfonate vesicles. Langmuir 21 14 (2005) 6210-6219
175. Tippin T.K., and Thakker D.R. Biorelevant refinement of the Caco-2 cell culture model to assess efficacy of paracellular permeability enhancers. J. Pharm. Sci. 97 5 (2008) 1977-1992
176. Heerklotz H. Interactions of surfactants with lipid membranes. Q. Rev. Biophys. 41 3-4 (2008) 205-264
177. Morigaki K., Walde P., Misran M., and Robinson B.H. Thermodynamic and kinetic stability. Properties of micelles and vesicles formed by the decanoic acid/decanoate system. Coll. Surf. A 213 1 (2003) 37-44
178. Kanicky J.R., Poniatowski A.F., Mehta N.R., and Shah D.O. Cooperativity among molecules at interfaces in relation to various technological processes: effect of chain length on the pK(a) of fatty acid salt solutions. Langmuir 16 1 (2000) 172-177
179. Muranishi S. Absorption enhancers. Crit. Rev. Ther. Drug Carrier Syst. 7 1 (1990) 1-33
180. Swenson S.E., and Curatolo W.J. (C) Means to enhance penetration: (2) Intestinal permeability enhancement for proteins, peptides and other polar drugs: mechanisms and potential toxicity. Adv. Drug Deliv. Rev. 8 1 (1992) 39-92
181. Whitehead K., Karr N., and Mitragotri S. Safe and effective permeation enhancers for oral drug delivery. Pharm. Res. 25 8 (2008) 1782-1788
182. Sharma P., Varma M.V., Chawla H.P., and Panchagnula R. Absorption enhancement, mechanistic and toxicity studies of medium chain fatty acids, cyclodextrins and bile salts as peroral absorption enhancers. Farmaco 60 11-12 (2005) 884-893
183. Turunen T.M., Urtti A., Paronen P., Audus K.L., and Rytting J.H. Effect of some penetration enhancers on epithelial membrane lipid domains: evidence from fluorescence spectroscopy studies. Pharm. Res. 11 2 (1994) 288-294
184. Noriyuki M., Mariko K., Yasuko N., Shozo M., and Hitoshi S. Mechanism for the inducement of the intestinal absorption of poorly absorbed drugs by mixed micelles I. Effects of various lipid-bile salt mixed micelles on the intestinal absorption of streptomycin in rat. Int. J. Pharm. 4 4 (1980) 271-279
185. Noriyuki M., Yasuko N., Mariko K., Shozo M., and Hitoshi S. Mechanism for the inducement of the intestinal absorption of poorly absorbed drugs by mixed micelles II. Effect of the incorporation of various lipids on the permeability of liposomal membranes. Int. J. Pharm. 4 4 (1980) 281-290
186. Muranushi N., Takagi N., Muranishi S., and Sezaki H. Effect of fatty acids and monoglycerides on permeability of lipid bilayer. Chem. Phys. Lipids 28 3 (1981) 269-279
187. Yamamoto A., and Muranishi S. Rectal drug delivery systems Improvement of rectal peptide absorption by absorption enhancers, protease inhibitors and chemical modification. Adv. Drug Deliv. Rev. 28 2 (1997) 275-299
188. Jones M.N. Surfactants in membrane solubilisation. Int. J. Pharm. 177 2 (1999) 137-159
189. Lichtenberg D. Characterization of the solubilization of lipid bilayers by surfactants. Biochim. Biophys. Acta 821 3 (1985) 470-478
190. Nishimura K., Nozaki Y., Yoshimi A., Nakamura S., Kitagawa M., Kakeya N., and Kitao K. Studies on the promoting effects of carboxylic acid derivatives on the rectal absorption of beta-lactam antibiotics in rats. Chem. Pharm. Bull. 33 1 (1985) 282-291
191. Constantinides P.P., Welzel G., Ellens H., Smith P.L., Sturgis S., Yiv S.H., and Owen A.B. Water-in-oil microemulsions containing medium-chain fatty acids/salts: formulation and intestinal absorption enhancement evaluation. Pharm. Res. 13 2 (1996) 210-215
192. Godin B., and Touitou E. Enhancers for enteral delivery of macromolecules with emphasis on surfactants. In: Touitou E., and Barry B.W. (Eds). Enhancement in Drug Delivery (2006), CRC Press 37-56
193. Kamm W., Jonczyk A., Jung T., Luckenbach G., Raddatz P., and Kissel T. Evaluation of absorption enhancement for a potent cyclopeptidic alpha(nu)beta(3)-antagonist in a human intestinal cell line (Caco-2). Eur. J. Pharm. Sci. 10 3 (2000) 205-214
194. Lapre J.A., Termont D.S., Groen A.K., and Van der Meer R. Lytic effects of mixed micelles of fatty acids and bile acids. Am. J. Physiol. 263 3 Pt 1 (1992) G333-337
195. Porter C.J., Trevaskis N.L., and Charman W.N. Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs. Nat. Rev. 6 3 (2007) 231-248
196. Mukherjee T., Squillantea E., Gillespieb M., and Shao J. Transepithelial electrical resistance is not a reliable measurement of the Caco-2 monolayer integrity in Transwell. Drug. Del. 11 1 (2004) 11-18
197. Sharma P., Varma M.V., Chawla H.P., and Panchagnula R. Relationship between lipophilicity of BCS class III and IV drugs and the functional activity of peroral absorption enhancers. Farmaco 60 11-12 (2005) 870-873
198. Shima M., Kimura Y., Adachi S., and Matsuno R. The relationship between transport-enhancement effects and cell viability by capric acid sodium salt, monocaprin, and dicaproin. Biosci. Biotechnol. Biochem. 62 1 (1998) 83-86
199. Tomita M., Shiga M., Hayashi M., and Awazu S. Enhancement of colonic drug absorption by the paracellular permeation route. Pharm. Res. 5 6 (1988) 341-346
200. Sharma P., Varma M.V., Chawla H.P., and Panchagnula R. In situ and in vivo efficacy of peroral absorption enhancers in rats and correlation to in vitro mechanistic studies. Farmaco 60 11-12 (2005) 874-883
201. Sugita Y., Takao K., Toyama Y., and Shirahata A. Enhancement of intestinal absorption of macromolecules by spermine in rats. Amino Acids 33 2 (2007) 253-260
202. Kinouchi Y., Takeichi Y., and Yata N. A novel method for the preclinical assessment of rectal irritation. J. Pharm. Pharmacol. 48 3 (1996) 310-315
203. Curatolo W., and Ochoa R. Safety assessment of intestinal permeability enhancers. In: De Boer A.G. (Ed). Drug Absorption Enhancement Concepts, Possibilities, Limitations and Trends (1994), Harwood Academic 155-175
204. Geary R., Yu R., Kim T.-W., Levin A., Dokka S., Tillman L.G., and Hardee G. Pharmacokinetics and tolerability of daily oral antisense oligonucleotide, ISIS 301012, in mice and dogs for 13 weeks. AAPS PharmSciTech 7 S2 (2005)
205. Raoof A.A., Chiu P., Ramtoola Z., Cumming I.K., Teng C., Weinbach S.P., Hardee G.E., Levin A.A., and Geary R.S. Oral bioavailability and multiple dose tolerability of an antisense oligonucleotide tablet formulated with sodium caprate. J. Pharm. Sci. 93 6 (2004) 1431-1439
206. Blikslager A.T., Moeser A.J., Gookin J.L., Jones S.L., and Odle J. Restoration of barrier function in injured intestinal mucosa. Physiol. Rev. 87 2 (2007) 545-564
207. Moore R., Carlson S., and Madara J.L. Villus contraction aids repair of intestinal epithelium after injury. Am. J. Physiol. 257 2 Pt 1 (1989) G274-283
208. Feil W., Lacy E.R., Wong Y.M., Burger D., Wenzl E., Starlinger M., and Schiessel R. Rapid epithelial restitution of human and rabbit colonic mucosa. Gastroenterology 97 3 (1989) 685-701
209. Moore R., Carlson S., and Madara J.L. Rapid barrier restitution in an in vitro model of intestinal epithelial injury. Lab. Invest. 60 2 (1989) 237-244
210. Swenson E.S., Milisen W.B., and Curatolo W. Intestinal permeability enhancement: efficacy, acute local toxicity, and reversibility. Pharm. Res. 11 8 (1994) 1132-1142
211. Nakanishi K., Masada M., and Nadai T. Effect of pharmaceutical adjuvants on the rectal permeability of drugs. III. Effect of repeated administration and recovery of the permeability. Chem. Pharm. Bull. 31 11 (1983) 4161-4166
212. Kvietys P.R., Specian R.D., Grisham M.B., and Tso P. Jejunal mucosal injury and restitution: role of hydrolytic products of food digestion. Am. J. Physiol. 261 3 Pt 1 (1991) G384-391
213. Purohit V., Bode J.C., Bode C., Brenner D.A., Choudhry M.A., Hamilton F., Kang Y.J., Keshavarzian A., Rao R., Sartor R.B., Swanson C., and Turner J.R. Alcohol, intestinal bacterial growth, intestinal permeability to endotoxin, and medical consequences, summary of a symposium. Alcohol (Fayetteville, N.Y) 42 5 (2008) 349-361
214. van Hoogdalem E.J., de Boer A.G., and Breimer D.D. Pharmacokinetics of rectal drug administration, Part II. Clinical applications of peripherally acting drugs, and conclusions. Clin. Pharmacokinet. 21 2 (1991) 110-128
215. Barrett K.E., and Keely S.J. Chloride secretion by the intestinal epithelium: molecular basis and regulatory aspects. Annu. Rev. Physiol. 62 (2000) 535-572
216. Maher S., Feighery L., Brayden D.J., and McClean S. Melittin as a permeability enhancer II: in vitro investigations in human mucus secreting intestinal monolayers and rat colonic mucosae. Pharm. Res. 24 7 (2007) 1346-1356
217. Shiga M., Hayashi M., Horie T., and Awazu S. Promotion of drug rectal absorption related to water absorption. Chem. Pharm. Bull. 34 5 (1986) 2254-2256
218. Cox A.B., Rawlinson L.A., Baird A.W., Bzik V., and Brayden D.J. In vitro interactions between the oral absorption promoter, sodium caprate (C(10)) and S. typhimurium in rat intestinal ileal mucosae. Pharm. Res. 25 1 (2008) 114-122
219. Sprong R.C., Hulstein M.F., and Van der Meer R. Bactericidal activities of milk lipids. Antimicrob. Agents Chemother. 45 4 (2001) 1298-1301
220. Thormar H., Isaacs C.E., Brown H.R., Barshatzky M.R., and Pessolano T. Inactivation of enveloped viruses and killing of cells by fatty acids and monoglycerides. Antimicrob. Agents Chemother. 31 1 (1987) 27-31
221. Schnaitman C.A. Solubilization of the cytoplasmic membrane of Escherichia coli by Triton X-100. J. Bacteriol. 108 1 (1971) 545-552
222. Kabara J.J., Swieczkowski D.M., Conley A.J., and Truant J.P. Fatty acids and derivatives as antimicrobial agents. Antimicrob. Agents Chemother. 2 1 (1972) 23-28
223. Rayan P., Stenzel D., and McDonnell P.A. The effects of saturated fatty acids on Giardia duodenalis trophozoites in vitro. Parasitol. Res. 97 3 (2005) 191-200
224. Gregory L.G., Harbottle R.P., Lawrence L., Knapton H.J., Themis M., and Coutelle C. Enhancement of adenovirus-mediated gene transfer to the airways by DEAE dextran and sodium caprate in vivo. Mol. Ther. 7 1 (2003) 19-26
225. Johnson L.G., Vanhook M.K., Coyne C.B., Haykal-Coates N., and Gavett S.H. Safety and efficiency of modulating paracellular permeability to enhance airway epithelial gene transfer in vivo. Hum. Gene Ther. 14 8 (2003) 729-747
226. Lennernas H., Gjellan K., Hallgren R., and Graffner C. The influence of caprate on rectal absorption of phenoxymethylpenicillin: experience from an in-vivo perfusion in humans. J. Pharm. Pharmacol. 54 4 (2002) 499-508
227. Motohiro T., Aramaki M., Tanaka K., Koga T., Shimada Y., Tomita N., Sakata Y., Fujimoto T., Nishiyama T., Kuda N., et al. Fundamental study on ceftizoxime suppositories in adults and children. Jpn. J. Antibiot. 38 10 (1985) 3013-3056
228. Bergogne-Berezin E., and Bryskier A. The suppository form of antibiotic administration: pharmacokinetics and clinical application. J. Antimicrob. Chemother. 43 2 (1999) 177-185
229. Fujii R., and McCracken G.H. Antibiotic suppositories. In: Ishigami J. (Ed). Proceedings of the 14th International Congress of Chemotherapy. Recent Advances in Chemotherapy. Section 3 (1985), University of Tokyo Press, Tokyo 2709-2715
230. Motohiro T., Aramaki M., Oda K., Kawakami A., Tanaka K., Koga T., Shimada Y., Tomita S., Sakata Y., et al. Antibiotic suppositories. Pediatr. Int. 28 4 (2007) 535-543
231. Motohiro T., Aramaki M., Oda K., Kawakami A., Tanaka K., Koga T., Shimada Y., Tomita S., Sakata Y., et al. Antibiotic suppositories. Acta Paediatr. 28 4 (1986) 535-543
232. Fujioka T., Kondou T., Fukuhara A., Tounou S., Mine M., Mataki N., Hanada K., Ozaka M., Mitani K., Nakaya T., Iwai T., and Miyakawa H. Efficacy of a glycyrrhizin suppository for the treatment of chronic hepatitis C: a pilot study. Hepatol. Res. 26 1 (2003) 10-14
233. Anonymous, Swedis database (http://sweweb.mpa.se/swedisii/). Data obtained from the Medical Products Agency, Uppsala, Sweden.
234. Bergstrom B.K., Bertilson S.O., and Movin G. Clinical evaluation of rectally administered ampicillin in acute otitis media. J. Int. Med. Res. 16 5 (1988) 376-385
235. Teng C.-L., Cook P.D., Tillman L., Hardee G.E., Ecker D.J., and Manoharan M. US Patent 6747014 (2004)
236. Wang Y. Isis-301012 - antisense inhibitor of apolipoprotein B treatment of lipoprotein disorders. Drug Future 32 8 (2007) 699-702
237. Cumming K.I., Ramtoola Z., and Leonard T.W. US Patent Application 11/400689 (2007)
238. Leonard T., Coughlan D., Adamczyk B., O'Toole E., and Lee A. A bioavailability and pharmacodynamic study of GIPET™ formulations of acyline, a GnRH antagonist, administered by intraduodenal instillation in beagle dogs. AAPS PharmSciTech 9 S2 (2007)
239. Amory J.K., Leonard T.W., Page S.T., O'Toole E., McKenna M.J., and Bremner W.J. Oral administration of the GnRH antagonist acyline, in a GIPET((R))-enhanced tablet form, acutely suppresses serum testosterone in normal men: single-dose pharmacokinetics and pharmacodynamics. Cancer Chemother. Pharmacol. 64 3 (2009) 641-645
240. Leonard T.W., Adamczyk B., Lee A., and O'Toole E. Eliminating the bisphosphonate dosing ritual with an improved dosage form of alendronate, MER-103. Menopause 14 6 (2007) 1098 2007
241. Cullen A., McHugh C., Feeney O., O'Toole E., and Leonard T. A bioavailability study of GIPET™ formulations of zoledronic acid, administered by intraduodenal instillation in beagle dogs. AAPS PharmSciTech 9 S2 (2007)
242. McHugh C., Madigan K., Walsh A., Fox J., Leonard T.W., and Quint J.B. MER-101-03, a multicenter, phase II study to compare MER-101 20 mg tablets to intravenous zoledronic acid 4 mg in prostate cancer patients. J. Clin. Oncol. 27 15 suppl. (2009) 5161
243. Maher S., Brayden D.J., Feighery L., and McClean S. Cracking the junction: update on the progress of gastrointestinal absorption enhancement in the delivery of poorly absorbed drugs. Crit. Rev. Ther. Drug Carrier Syst. 25 2 (2008) 117-168
244. Nava P., Lopez S., Arias C.F., Islas S., and Gonzalez-Mariscal L. The rotavirus surface protein VP8 modulates the gate and fence function of tight junctions in epithelial cells. J. Cell Sci. 117 Pt 23 (2004) 5509-5519
245. Bjarnason I. Intestinal permeability. Gut 35 1 Suppl. (1994) S18-22
246. Wolfe M.M., Lichtenstein D.R., and Singh G. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N. Engl. J. Med. 340 24 (1999) 1888-1899
247. Vervarcke S., Ollevier F., Kinget R., and Michoel A. Oral vaccination of African catfish with Vibrio anguillarum O2: effect on antigen uptake and immune response by absorption enhancers in lag time coated pellets. Fish Shellfish Immun. 16 3 (2004) 407-414
248. Sechter I., Touitou E., and Donbrow M. The influence of a non-ionic surfactant on rectal absorption of virus particles. Arch. Virol. 106 1-2 (1989) 141-143
249. Twiss I.M., Burggraaf J., Schoemaker R.C., van Elburg R.M., den Hartigh J., Cohen A.F., and Vermeij P. The sugar absorption test in the evaluation of the gastrointestinal intolerance to bisphosphonates: studies with oral pamidronate. Clin. Pharmacol. Ther. 69 6 (2001) 431-437
250. Dastych M., Dastych Jr. M., Novotna H., and Cihalova J. Lactulose/mannitol test and specificity, sensitivity, and area under curve of intestinal permeability parameters in patients with liver cirrhosis and Crohn's disease. Dig. Dis. Sci. 53 10 (2008) 2789-2792
251. Lambert G.P., Broussard L.J., Mason B.L., Mauermann W.J., and Gisolfi C.V. Gastrointestinal permeability during exercise: effects of aspirin and energy-containing beverages. J. Appl. Physiol. 90 6 (2001) 2075-2080
252. Ryan A.J., Chang R.T., and Gisolfi C.V. Gastrointestinal permeability following aspirin intake and prolonged running. Med. Sci. Sport Exer. 28 6 (1996) 698-705
253. Raiman J., Tormalehto S., Yritys K., Junginger H.E., and Monkkonen J. Effects of various absorption enhancers on transport of clodronate through Caco-2 cells. Int. J. Pharm. 261 1-2 (2003) 129-136
254. Liu D.Z., LeCluyse E.L., and Thakker D.R. Dodecylphosphocholine-mediated enhancement of paracellular permeability and cytotoxicity in Caco-2 cell monolayers. J. Pharm. Sci. 88 11 (1999) 1161-1168
255. Motlekar N.A., Srivenugopal K.S., Wachtel M.S., and Youan B.B. Oral delivery of low-molecular-weight heparin using sodium caprate as absorption enhancer reaches therapeutic levels. J. Drug Target. 13 10 (2005) 573-583
256. Zornoza T., Cano-Cebrian M.J., Nalda-Molina R., Guerri C., Granero L., and Polache A. Assessment and modulation of acamprosate intestinal absorption: comparative studies using in situ, in vitro (CACO-2 cell monolayers) and in vivo models. Eur. J. Pharm. Sci. 22 5 (2004) 347-356
257. Zhou L., Chow M.S.S., and Zuo Z. Effect of sodium caprate on the oral absorptions of danshensu and salvianolic acid B. Int. J. Pharm. 379 1 (2009) 109-118
258. Sakai M., Imai T., Ohtake H., Azuma H., and Otagiri M. Effects of absorption enhancers on the transport of model compounds in Caco-2 cell monolayers: assessment by confocal laser scanning microscopy. J. Pharm. Sci. 86 7 (1997) 779-785
259. Hayashi M., and Tomita M. Mechanistic analysis for drug permeation through intestinal membrane. Drug Metab. Pharmacokinet. 22 2 (2007) 67-77
260. Nakamura K., Maitani Y., and Takayama K. The enhancing effect of nasal absorption of FITC-dextran 4, 400 by beta-sitosterol beta-d-glucoside in rabbits. J. Control. Release 79 1-3 (2002) 147-155
261. Tomita M., Hayashi M., and Awazu S. Comparison of absorption-enhancing effect between sodium caprate and disodium ethylenediaminetetraacetate in Caco-2 cells. Biol. Pharm. Bull. 17 5 (1994) 753-755
262. Badawi A.A., El-Laithy H.M., and Abu Amara H.M. Optimization and evaluation of amoxicillin medium chain fatty acids/salts microemulsions: intestinal absorption and cytotoxicity. J. Drug Deliv. Sci. Technol. 18 2 (2008) 109-118
263. Ogiso T., Iwaki M., Kashitani Y., and Yamashita K. Enhancement by fatty acids of the rectal absorption of propranolol: in vitro evaluation in the rat. J. Pharmacobiodyn. 14 7 (1991) 385-391
264. Nishiura A., and Lee V.H.L. Paracellular transport of proteolytically labile peptides in the rabbit intestine. Pharm. Res. 9 10 suppl. (1992) S216
265. Kakeya N. Development of new adjuvants for enhanced rectal absorption. In: Ishigami J. (Ed). Proceedings of the 14th International Congress of Chemotherapy. Recent Advances in Chemotherapy. Section 3 (1985), University of Tokyo Press, Tokyo 2711
266. 2EDTA and sodium glycocholate on intestinal absorption of insulin. Biol. Pharm. Bull. 16 1 (1993) 68-72
267. Mori S., Matsuura A., Rama Prasad Y.V., and Takada K. Studies on the intestinal absorption of low molecular weight heparin using saturated fatty acids and their derivatives as an absorption enhancer in rats. Biol. Pharm. Bull. 27 3 (2004) 418-421
268. Lin X., Xu D.S., Feng Y., Li S.M., Lu Z.L., and Shen L. Release-controlling absorption enhancement of enterally administered Ophiopogon japonicus polysaccharide by sodium caprate in rats. J. Pharm. Sci. 95 11 (2006) 2534-2542
269. Kamio Y., Saito Y., Utoguchi N., Kondoh M., Koizumi N., Fujii M., and Watanabe Y. Epinephrine is an enhancer of rat intestinal absorption. J. Control. Release 102 3 (2005) 563-568
270. Numata N., Takahashi K., Mizuno N., Utoguchi N., Watanabe Y., Matsumoto M., and Mayumi T. Improvement of intestinal absorption of macromolecules by nitric oxide donor. J. Pharm. Sci. 89 10 (2000) 1296-1304
271. Yamamoto A., Uchiyama T., Nishikawa R., Fujita T., and Muranishi S. Effectiveness and toxicity screening of various absorption enhancers in the rat small intestine: effects of absorption enhancers on the intestinal absorption of phenol red and the release of protein and phospholipids from the intestinal membrane. J. Pharm. Pharmacol. 48 12 (1996) 1285-1289
272. Takahashi K., Murakami T., Kamata A., Yumoto R., Higashi Y., and Yata N. Pharmacokinetic analysis of the absorption enhancing action of decanoic acid and its derivatives in rats. Pharm. Res. 11 3 (1994) 388-392
273. Higaki K., Yata T., Sone M., Ogawara K., and Kimura T. Estimation of absorption enhancement by medium-chain fatty acids in rat large intestine. Res. Comm. Mol. Pathol. Pharmacol. 109 3-4 (2001) 231-240
274. Miyake M., Oka Y., Minami T., Toguchi H., Odomi M., Ogawara K., Higaki K., and Kimura T. Combinatorial use of sodium laurate with taurine or l-glutamine enhances colonic absorption of rebamipide, poorly absorbable antiulcer drug, without any serious histopathological mucosal damages. J. Pharm. Sci. 92 4 (2003) 911-921
275. Uchiyama T., Yamamoto A., Hatano H., Fujita T., and Muranishi S. Effectiveness and toxicity screening of various absorption enhancers in the large intestine: intestinal absorption of phenol red and protein and phospholipid release from the intestinal membrane. Biol. Pharm. Bull. 19 12 (1996) 1618-1621
276. Sasaki K., Yonebayashi S., Yoshida M., Shimizu K., Aotsuka T., and Takayama K. Improvement in the bioavailability of poorly absorbed glycyrrhizin via various non-vascular administration routes in rats. Int. J. Pharm. 265 1-2 (2003) 95-102
277. Kinouchi Y., and Yata N. Effect of some amino acids on the rectal irritation caused by sodium caprate in conscious rats. Biol. Pharm. Bull. 19 3 (1996) 375-378
278. Van Hoogdalem E.J., De Boer A.G., and Breimer D.D. Rectal absorption enhancement of rate-controlled delivered ampicillin sodium by sodium decanoate in conscious rats. Pharm. Weekbl. 10 2 (1988) 76-79
279. Mishima M., Nagatomi A., Yamakita T., Miura Y., and Tsuzuki O. Promotion of rectal absorption of sodium ampicillin by disodium glycyrrhetinic acid 3 beta-O-monohemiphthalate in rats. Biol. Pharm. Bull. 18 4 (1995) 566-570
280. van Hoogdalem E.J., Hardens M.A., de Boer A.G., and Breimer D.D. Absorption enhancement of rectally infused cefoxitin sodium by medium-chain fatty acids in conscious rats: concentration-effect relationship. Pharm. Res. 5 7 (1988) 453-456
281. Yamazaki M., Itoh S., Sawanoi M., Kobayashi M., Suzuki S., Komatsu T., and Tanabe K. The effect of fatty acids on the rectal absorption of acyclovir in rats. J. Pharm. Pharmacol. 42 6 (1990) 441-443
282. Tanabe K., Miyaji N., Tatara N., Itoh S., and Yamazaki M. Effects of suppository bases on rectal absorption of atenolol. Jpn. J. Hosp. Pharm. 15 3 (1989) 202-208
283. Aungst B.J., Saitoh H., Burcham D.L., Huang S.-M., Mousa S.A., and Hussain M.A. Enhancement of the intestinal absorption of peptides and nonpeptides. J. Control. Release 41 1-2 (1996) 19-31
284. Radwan M.A., and Aboul-Enein H.Y. The effect of oral absorption enhancers on the in vivo performance of insulin-loaded poly(ethylcyanoacrylate) nanospheres in diabetic rats. J. Microencapsul. 19 2 (2002) 225-235
285. Miyake M., Minami T., Oka Y., Kamada N., Yamazaki H., Kato Y., Mukai T., Toguchi H., Odomi M., Ogawara K., Higaki K., and Kimura T. Optimization of suppository preparation containing sodium laurate and taurine that can safely improve rectal absorption of rebamipide. Biol. Pharm. Bull. 29 2 (2006) 330-335
286. Matsumoto Y., Watanabe Y., Yamamoto I., Shinozaki S., Kakuhari T., Matsumoto M., Obayashi M., and Anjou S. Rectal absorption enhancement of vancomycin in rabbits by sodium hyaluronate or medium-chain fatty acids. Yakuzaigaku 54 1 (1994) 29-34
287. Dos Santos I., Fawaz F., Lagueny A.M., and Bonini F. Improvement of norfloxacin oral bioavailability by EDTA and sodium caprate. Int. J. Pharm. 260 1 (2003) 1-4
288. Aungst B.J., Saitoh H., Gerard C., Mousa S.A., Burcham D.L., Huang S.M., and Hussain M. Oral absorption enhancement of acyclic peptide fibrinogen antagonist using sodium caprate. Pharm. Res. 12 9 suppl. (1995) S291
289. Takeichi Y., Baba K., Kinouchi Y., Iida Y., Umeno Y., Muranishi S., and Nakai Y. Combinative improving effect of increased solubility and the use of absorption enhancers on the rectal absorption of uracil in beagle dogs. Chem. Pharm. Bull. 38 9 (1990) 2547-2551
290. Sakamoto H., Takahashi Y., Sakamoto M., Misumi K., Kawasaki Y., and Okamoto K. Rectal absorption of ampicillin suppository in cattle. Animal Sci. Technol. 66 11 (1995) 969-975
291. Campbell A.N., and Lakshmin G.R. Conductances and surface tensions of aqueous solutions of sodium decanoate sodium laurate and sodium myristate at 25 degrees and 35 degrees. Can. J. Chem. 43 6 (1965) 1729-1737
292. Schultheiss G., Ribeiro R., and Diener M. Fatty acids inhibit anion secretion in rat colon: apical and basolateral action sites. Pflug. Arch. Eur. J. Phy. 442 4 (2001) 603-613
293. Kellum R.E. Acne vulgaris. Studies in pathogenesis: relative irritancy of free fatty acids from C2 to C16. Arch. Dermatol. 97 6 (1968) 722-726
294. Tomlin K.L., Clark S.R., and Ceri H. Green and red fluorescent protein vectors for use in biofilm studies of the intrinsically resistant Burkholderia cepacia complex. J. Microbiol. Meth. 57 1 (2004) 95-106